Product logins

Find logins to all Clarivate products below.


ICOTYDE™ (icotrokinra)

Learn how ICOTYDE is changing the plaque psoriasis landscape.

Latest news

52-week data from the phase 3 ICONIC-ADVANCE 1 and 2 and ICONIC-LEAD studies show high rates of complete skin clearance 52-week data from the phase 3 ICONIC-ADVANCE 1 and 2 and ICONIC-LEAD studies show high rates of complete skin clearance
March 28, 2026
52-week data from the phase 3 ICONIC-ADVANCE 1 and 2 and ICONIC-LEAD studies show high rates of complete skin clearance
ICONIC-ADVANCE 1 and 2 studies: rates of completely clear skin (PASI 100) increased from 41% to 49% and 33% to 48% from week 24 to week 52, respectively, in participants with moderate-to-severe plaque psoriasis in the treatment arm, with no new safety signals. ICONIC-LEAD: nearly 60% of adolescents achieved completely clear skin (57% PASI 100, 61% IGA 0) at week 52 with ICOTYDE, and 86% achieved PASI 90 response at one year, with 92% maintaining that response from week 24 to week 52. Throughout the 52 weeks, no increase in AE incidence was observed.
ICOTYDE™ (icotrokinra) approved by the FDA as the first IL-23R-targeted oral peptide to treat plaque psoriasis ICOTYDE™ (icotrokinra) approved by the FDA as the first IL-23R-targeted oral peptide to treat plaque psoriasis
March 18, 2026
ICOTYDE™ (icotrokinra) approved by the FDA as the first IL-23R-targeted oral peptide to treat plaque psoriasis
ICOTYDE is now approved for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg and who are candidates for systemic therapy or phototherapy. This makes ICOTYDE the first and only oral interleukin-23 (IL-23) receptor antagonist approved for this indication. Approval was based on evidence across four phase 3 studies in the ICONIC clinical development program.
chevron_left
chevron_right

What is icotrokinra (ICOTYDE) and what sets it apart

ICOTYDE is the first-to-market targeted oral peptide designed to block the interleukin (IL)-23 receptor, which plays a key role in the inflammatory process in moderate-to-severe plaque psoriasis as well as ulcerative colitis.

ICOTYDE aims to set a new standard in oral psoriasis treatment, potentially challenging early biologic use while offering an effective, convenient, non-injectable alternative without compromising efficacy.

About ICOTYDE

  • Company: Johnson & Johnson
  • Type: IL-23 receptor antagonist
  • Usage: Once-daily oral administration to treat plaque psoriasis
    Also being evaluated to treat psoriatic arthritis and ulcerative colitis
  • When will icotrokinra be available?
    Expected launch 2026: United States
    Expected launch 2027: European Union, Japan

Icotrokinra sales and success forecasts

$1.5bn
expected sales in the G7 markets in 2031
95%
probability of success for icotrokinra in the United States

I consider icotrokinra to be the most promising oral drug in development. It appears to be highly effective with few side effects. It could replace biological agents such as TNF-α inhibitors or secukinumab.

Dermatologist Japan

Drugs in the 2026 list